ChulaCov19 Vaccine in Healthy Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

192 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-03

Study Completion Date

2022-12-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be conducted in 2 phases. Phase 1 of this study will be a single-centre, open label, dose escalation first in human (FIH) study conducted in 2 groups of healthy participants. Group 1 will enrol adults aged 18-55 years (inclusive); Group 2 will enroll elderly adults (elderly) aged 56-75 years (inclusive).

Phase 2 of this study will be a single centre, the proposed design will be observer-blind, placebo-controlled study to assess the safety, reactogenicity, and immunogenicity of ChulaCov19 vaccine in healthy adults (18-75 years of age inclusive).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine

NCT05231369

Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine +4 more

UNKNOWN PHASE1

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

NCT04449276

Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2 +1 more

COMPLETED PHASE1

Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults

NCT05605470

COVID-19, SARS CoV 2 Infection

COMPLETED PHASE2

A Study of Ad26.COV2.S in Adults (COVID-19)

NCT04436276

Covid-19 Prevention

COMPLETED PHASE1/PHASE2

Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine

NCT04445194

Coronavirus

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be conducted as a combined phase 1/2 study in healthy participants.

The first phase of the study will evaluate the safety, tolerability, and reactogenicity of escalating doses (10 µg, 25 µg, and 50 µg) of the ChulaCov19 vaccine, administered intramuscularly (IM) according to a repeat vaccination schedule (given 21 days apart) in healthy adults aged 18-55 years and in elderly adults aged 56-75 years, up to Visit 10 (Day 50 ±3).

The second phase of the study will evaluate the safety, tolerability, and reactogenicity of escalating doses of the ChulaCov19 vaccine, administered intramuscularly (IM) according to a repeat vaccination schedule (given 21 days apart) in healthy adults aged 18--75 years, up to Visit 10 (Day 50 ±3). The study will also evaluate the immunogenicity measured as neutralising antibody titre (measured by Micro-viral neutralising test \[MicroVNT\]) following repeat vaccination of escalating doses of the ChulaCov19 vaccine, administered IM according to a repeat vaccination schedule (given 21 days apart) in healthy adults aged 18-75 years, at Visit 9 (Day 29 +3).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Vaccine Safety Issues

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Phase 1: Group 1 (healthy adults aged 18 to 55 years) and Group 2 (elderlies aged 56 to 75 years) will be enrolled sequentially in an ascending dose fashion (10 µg, 25 µg, 50 µg). Up to 36 eligible healthy volunteers for each of the 2 age groups will be enrolled into 1 of 3 treatment cohorts (12 participants/ cohort). For each cohort, if only 1 participant withdraws prior to the second vaccination, no replacement is deemed necessary. For each cohort, if more than 1 participant withdraws prior to the second vaccination all withdrawn participants will be replaced.

Phase 2: The Phase 2 adult cohorts will include adults between 18 and 59 years of age (inclusive). Participants in the Phase 2 will be enrolled into at least 1 dose level cohort with a vaccination dose of 50 ug which was determined by DSMB and SRPT review and approval of the applicable Phase 1 data. Phase 2 treatment group will consist of participants randomly assigned to active treatment versus placebo in a ratio of 4:1.

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Intervention Type OTHER

Saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ChulaCov19 vaccine

SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine

Intervention Type BIOLOGICAL

Placebo

Saline

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants must be able to communicate effectively with study personnel and considered reliable, willing, and cooperative in terms of compliance with the protocol requirements.
2. Participants must sign the written informed consent form prior to undertaking any protocol related procedures.
3. Participants must have a body mass index (BMI) at Screening, calculated as the body mass divided (in kilograms \[kg\]) by the square of the body height (in metres \[m\]) of 18.0-30.0 kg/m2, inclusive.
4. Participants must have haematology, clinical chemistry, coagulation (for all participants in Phase 1, and, only if applicable, for participants in Phase 2), and urinalysis test results that are not deviating from the normal reference range by age and gender to a clinically relevant extent at Screening.
5. Males must be surgically sterile (\>30 days since vasectomy with no viable sperm), practice true abstinence or, if engaged in sexual relations with a female of child-bearing potential, the participants and their partner must use an acceptable, highly effective, double-barrier contraceptive method\* from Screening and for a period of at least 60 days after the last dose of investigational vaccine.
6. Women of child-bearing potential must practice true abstinence or, if engaged in sexual relations with a male, they must agree to use highly effective (failure rate of \< 1% per year when used consistently and correctly), double-barrier contraceptive measures\* throughout the study and intend to continue use of contraception for at least 60 days following the last vaccination.

\* The PI is to assess the adequacy of methods of contraception on a case-by-case basis. These criteria do not apply if the participants are in a same-sex relationship.
7. Women of child-bearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin \[β-HCG\]) at Screening and a negative urine-based test within 24 hours prior to each investigational vaccine administration.
8. Women of non-child-bearing potential must:

1. be classified as being postmenopausal (defined as having a history of amenorrhea of at least one year), or
2. where history of amenorrhea is less than one year, female participants must have a follicle stimulating hormone (FSH) level \> 40 milli-international units per milliliter (mIU/mL), or
3. have a documented status of being surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation/salpingectomy).
9. Participants must be in general good health based on medical history and physical examination, as determined by the PI, at Screening.
10. Body temperature must be less than 37.8ºC, at Screening.
11. Pulse must be no greater than 100 beats per minute, at Screening.
12. Systolic blood pressure (SBP) must be between 85 to 150 millimetres of mercury (mm Hg), inclusive, at Screening.
13. Participants must agree to refrain from donating blood, plasma, ovules, sperm, or organs during the whole study.

Adult Participants (Group 1 of Phase 1) only
14. Must be a male or female aged 18-55 years (inclusive) at the time of enrolment.

Elderly Participants (Group 2 of Phase 1) only
15. Must be a male or female aged 56-75 years (inclusive) at the time of enrolment.

Participants for Phase 2 only
16. Must be a male or female aged 18 -59 years (inclusive) at the time of enrolment.

Exclusion Criteria

The presence of any of the following criteria will constitute cause for the exclusion of the participant:

1. Presence of clinically significant medical history, unstable chronic or acute disease, or physical, or laboratory findings that, in the opinion of the PI may potentially increase the expected risk of exposure to the investigational vaccine, compromise the safety of the participant, or interfere with any aspect of study conduct or interpretation of results. This will include asthma and any thrombocytopenia or bleeding disorder contraindicating IM vaccination.
2. Presence of self-reported or medically documented significant medical or psychiatric condition(s).
3. Presence of an acute illness, as determined by the participating site PI or appropriate sub-PI, with or without fever (temperature ≥ 38.0 ºC) within 72 hours prior to each vaccination.
4. Presence of birthmarks, tattoos, wound, or other skin conditions over the deltoid region of both arms that, in the PI's opinion, could reasonably obscure and interfere with evaluation of local ISRs.
5. Inadequate venous access to allow collection of blood samples.
6. Breastfeeding or planning to breastfeed from the time of the first vaccination through 60 days after the last vaccination, or pregnant as confirmed by a positive serum β-HCG pregnancy test at Screening or positive urine pregnancy test at subsequent clinic visits at timepoints as delineated in the schedule of assessments.
7. Received any prophylactic or therapeutic vaccine, or licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication, within 4 weeks of first vaccination or 5 half-lives (whichever is longer), or anticipate to do so in the follow-up period defined for this study.
8. Participant has previously participated in an investigational study involving LNPs (a component of the investigational vaccine assessed in this trial).
9. History of severe allergy (requiring hospital care), severe reaction to any drug or prior vaccination, or any known or suspected allergies or sensitivities to any component of the investigational vaccine or placebo.
10. History of ever had an anaphylaxis reaction to food, medication or vaccination.
11. Participant is immunosuppressed as caused by disease (such as HIV).
12. Chronic use (more than 14 continuous days) of or anticipated need to use, within the next 6 months, of any medications that may be associated with impaired immune responsiveness or with immunosuppression.
13. History of hepatitis B or hepatitis C infection.
14. Receipt of immunoglobulins or blood products within 3 months of first vaccination.
15. Requirement for antipyretic or analgesic medication on a daily or every other day basis from enrolment through 72 hours after vaccination.
16. Current use of any prescription or over-the-counter medications within 7 days prior to vaccination, unless approved by the PI.
17. History of alcohol or drug abuse that in the opinion of the PI could affect the participant's safety or compliance with study.
18. Participant unwilling to abstain from blood donation during the course of the study, and/or participation in any research study involving blood sampling (more than 450 mL /unit of blood), or blood donation to any blood bank during the 2 months prior to the Screening visit.
19. Close contact with anyone known to have SARS-CoV-2 infection within 30 days prior to vaccine administration.
20. Positive for SAR-CoV-2 by antibody IgG/IgM and anti spike IgG at screening
21. History of COVID-19 diagnosis (the criteria for COVID-19 diagnosis will follow the local guidelines).
22. On current treatment with investigational agents for prophylaxis of COVID-19.
23. Planning to travel outside Thailand from enrolment through 28 days after the second vaccination.
24. Residing in a nursing home or other skilled nursing facility or having a requirement for skilled nursing care.
25. Is a participant at high risk of SARS-CoV2 exposure in the opinion of the PI (e.g., healthcare workers, active health care workers with direct patient contact, emergency response personnel).

Elderly Participants (Group 2 of Phase 1) only
26. Chronically smoking (defined as ≥10 Pack years \[packs/day × years smoked\]) within the 12 months prior to enrolment.
27. Presence of co-morbidities that can be associated with an increased risk of severe COVID-19 Cancer, Chronic kidney diseases, COPD, cardiovascular disease, solid organ transplantation, DM type 2, HT, cerebrovascular disease, Obesity (BMI\> 30 kg/m2)

Participants for Phase 2 only
28. Presence of co-morbidities that can be associated with an increased risk of severe COVID-19 Cancer, Chronic kidney diseases, COPD, cardiovascular disease, solid organ transplantation, DM type 2, uncontrolled HT, cerebrovascular disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes